AgeX Therapeutics, Inc. (AGE) News

AgeX Therapeutics, Inc. (AGE): $0.50

0.05 (+11.58%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add AGE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#341 of 495

in industry

Filter AGE News Items

AGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGE News Highlights

  • For AGE, its 30 day story count is now at 2.
  • Over the past 16 days, the trend for AGE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about AGE are III and ST.

Latest AGE News From Around the Web

Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start off the final day of the trading week with a breakdown of the biggest pre-market stock movers for Friday!

William White on InvestorPlace | May 19, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday!

William White on InvestorPlace | May 18, 2023

AgeX Therapeutics Reports First Quarter 2023 Financial Results

ALAMEDA, Calif., May 12, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.

Yahoo | May 12, 2023

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif., April 26, 2023--AgeX Therapeutics , Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has st

Yahoo | April 26, 2023

AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results

ALAMEDA, Calif., March 31, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.

Yahoo | March 31, 2023

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

ALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio

Yahoo | November 25, 2022

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

ALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022.

Yahoo | November 10, 2022

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.

Yahoo | August 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8064 seconds.